- Research works
- 4 ▼ 85% vs 2013–17
- Citations
- 72 16.4 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 37% world 28%
Not ranked overall: BioBlast Pharma (Israel) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does BioBlast Pharma (Israel) publish most on?
By volume in 2022–2025: RNA regulation and disease, Genetic Neurodegenerative Diseases and Muscle Physiology and Disorders.
- 1 RNA regulation and disease Molecular Biology 0 works
- 2 Genetic Neurodegenerative Diseases Cellular and Molecular Neuroscience 0 works
- 3 Muscle Physiology and Disorders Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has BioBlast Pharma (Israel)'s research output changed?
Output in 2018–2022 was 85% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Tel Aviv
- Tel Aviv University
- Tel Aviv Sourasky Medical Center
- Assaf Harofeh Medical Center
- General Electric (Israel)
- Israel Atomic Energy Commission
- Clalit Health Services
- Academic College of Tel Aviv-Yafo
- Meta (Israel)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.